Objective: To evaluate persistence to denosumab treatment in osteoporotic postmenopausal women. Material and Methods: In this multicenter observational real practice study we recruited postmenopausal women affected by osteoporosis. We included women aged >50 years, able to receive a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were evaluated at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. Results: Eight hundred seventy women (with a mean age of 70 years and a mean body mass index of 24.8±4.1 kg/m2) were enrolled. At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was -2.76±1.14 standard deviations (SD) and the mean femoral neck T-score was - 2.49±0.80 SD. During the study, the persistence was 91.4% and the total dropouts were 75 (8.6%). After 12 months of treatment, persistence to therapy was over 99%that was maintained during all the study. The 4% of study population, who had started earlier therapy, reached 56 months of treatment with a persistence of 100%. Conclusion: This multicenter observational real practice study showed that persistence to denosumab treatment in our cohort of postmenopausal women was very high. High persistence to therapy could be particularly linked to the pharmacological schedule, but also to other factors such as frequency of visits, and opportunity to call the doctor could play a role in the persistence to treatment in these patients.

P751 EVALUATION OF DENOSUMAB PERSISTENCE IN POSTMENOPAUSAL WOMEN AFFECTED BY SEVERE OSTEOPOROSIS: A MULTICENTER OBSERVATIONAL REAL PRACTICE STUDY

F. Gimigliano;MORETTI A;G. Iolascon
2017

Abstract

Objective: To evaluate persistence to denosumab treatment in osteoporotic postmenopausal women. Material and Methods: In this multicenter observational real practice study we recruited postmenopausal women affected by osteoporosis. We included women aged >50 years, able to receive a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were evaluated at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. Results: Eight hundred seventy women (with a mean age of 70 years and a mean body mass index of 24.8±4.1 kg/m2) were enrolled. At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was -2.76±1.14 standard deviations (SD) and the mean femoral neck T-score was - 2.49±0.80 SD. During the study, the persistence was 91.4% and the total dropouts were 75 (8.6%). After 12 months of treatment, persistence to therapy was over 99%that was maintained during all the study. The 4% of study population, who had started earlier therapy, reached 56 months of treatment with a persistence of 100%. Conclusion: This multicenter observational real practice study showed that persistence to denosumab treatment in our cohort of postmenopausal women was very high. High persistence to therapy could be particularly linked to the pharmacological schedule, but also to other factors such as frequency of visits, and opportunity to call the doctor could play a role in the persistence to treatment in these patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11591/419608
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact